CORO2A

Summary

CORO2A (coronin 2A, HGNC:2255) is a protein-coding gene on chromosome 9q22.33, encoding Coronin-2A (Q92828).

This gene encodes a member of the WD repeat protein family. WD repeats are minimally conserved regions of approximately 40 amino acids typically bracketed by gly-his and trp-asp (GH-WD), which may facilitate formation of heterotrimeric or multiprotein complexes. Members of this family are involved in a variety of cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene regulation. This protein contains 5 WD repeats, and has a structural similarity with actin-binding proteins: the D. discoideum coronin and the human p57 protein, suggesting that this protein may also be an actin-binding protein that regulates cell motility. Alternative splicing of this gene generates 2 transcript variants.

Source: NCBI Gene 7464 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 117 total
• MANE Select transcript: NM_052820

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2255
Approved symbol	CORO2A
Name	coronin 2A
Location	9q22.33
Locus type	gene with protein product
Status	Approved
Aliases	IR10, WDR2
Ensembl gene	ENSG00000106789
Ensembl biotype	protein_coding
OMIM	602159
Entrez	7464

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 15 protein_coding

ENST00000343933, ENST00000375077, ENST00000871381, ENST00000871382, ENST00000871383, ENST00000871384, ENST00000871385, ENST00000871386, ENST00000871387, ENST00000930884, ENST00000930885, ENST00000930886, ENST00000948660, ENST00000948661, ENST00000948662

RefSeq mRNA: 2 — MANE Select: NM_052820 NM_003389, NM_052820

CCDS: CCDS6735

Canonical transcript exons

ENST00000375077 — 12 exons

Exon	Start	End
ENSE00000715194	98126549	98126823
ENSE00000715198	98128607	98128719
ENSE00000715200	98129794	98129890
ENSE00000715202	98130955	98131059
ENSE00000715204	98132185	98132301
ENSE00000715206	98133038	98133217
ENSE00000715209	98134806	98134955
ENSE00000715212	98137572	98137688
ENSE00001281957	98128170	98128260
ENSE00001353517	98192559	98192637
ENSE00001465684	98120975	98124905
ENSE00001465687	98157460	98157660

Expression profiles

Bgee: expression breadth ubiquitous, 216 present calls, max score 89.83.

FANTOM5 (CAGE): breadth broad, TPM avg 2.3477 / max 51.9883, expressed in 808 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
101673	2.3409	802
101670	0.0068	3

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	89.83	gold quality
duodenum	UBERON:0002114	88.71	gold quality
mucosa of transverse colon	UBERON:0004991	87.32	gold quality
gall bladder	UBERON:0002110	86.51	gold quality
lower esophagus mucosa	UBERON:0035834	84.52	gold quality
penis	UBERON:0000989	83.97	gold quality
bronchial epithelial cell	CL:0002328	83.79	gold quality
esophagus mucosa	UBERON:0002469	82.91	gold quality
colonic mucosa	UBERON:0000317	82.89	gold quality
rectum	UBERON:0001052	82.73	gold quality
dorsal root ganglion	UBERON:0000044	82.35	gold quality
pharyngeal mucosa	UBERON:0000355	81.72	gold quality
jejunum	UBERON:0002115	81.63	gold quality
small intestine	UBERON:0002108	81.59	gold quality
small intestine Peyer’s patch	UBERON:0003454	81.28	gold quality
mucosa of sigmoid colon	UBERON:0004993	80.50	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	80.48	gold quality
mucosa of paranasal sinus	UBERON:0005030	79.77	gold quality
oocyte	CL:0000023	79.54	gold quality
bone marrow	UBERON:0002371	79.27	gold quality
transverse colon	UBERON:0001157	79.21	gold quality
lower lobe of lung	UBERON:0008949	79.15	gold quality
ileal mucosa	UBERON:0000331	78.66	gold quality
buccal mucosa cell	CL:0002336	78.53	silver quality
esophagus squamous epithelium	UBERON:0006920	78.51	gold quality
trabecular bone tissue	UBERON:0002483	78.28	gold quality
epithelium of bronchus	UBERON:0002031	78.09	gold quality
bronchus	UBERON:0002185	77.91	gold quality
cerebellar hemisphere	UBERON:0002245	77.56	gold quality
cerebellar cortex	UBERON:0002129	77.55	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.84

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

131 targeting CORO2A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-130B-5P	99.83	68.50	1888
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-448	99.79	72.37	2103

Literature-anchored findings (GeneRIF, showing 6)

• This protein is one of 10-12 associated proteins in the purified N-CoR complex. (PMID:12628926)
• Coronin 2A and cofilin regulate a subset of focal-adhesion-turnover events. (PMID:19654210)
• The candidate marker CORO2A rs1985859 and the putative marker FAM101A rs7955740 may be of value for the prediction of radiosensitivity to preoperative colorectal tumors. (PMID:23490283)
• increased expression of coronin 2A is associated with the malignant phenotype of human colon carcinoma. (PMID:26373535)
• The regulation of CORO2A through the deubiquitinating activity of USP19 affected the transcriptional repression activity of the retinoic acid receptor (RAR), suggesting that USP19 may be involved in the regulation of RAR-mediated adipogenesis. (PMID:27129179)
• Molecular Pathogenesis of the Coronin Family: CORO2A Facilitates Migration and Invasion Abilities in Oral Squamous Cell Carcinoma. (PMID:34884487)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	coro2aa	ENSDARG00000005210
danio_rerio	coro2ab	ENSDARG00000095969
mus_musculus	Coro2a	ENSMUSG00000028337
rattus_norvegicus	Coro2a	ENSRNOG00000008901
drosophila_melanogaster	coro	FBGN0265935
caenorhabditis_elegans		WBGENE00000768

Paralogs (6): CORO1A (ENSG00000102879), CORO2B (ENSG00000103647), CORO1C (ENSG00000110880), CORO6 (ENSG00000167549), CORO1B (ENSG00000172725), CORO7 (ENSG00000262246)

Protein

Protein identifiers

Coronin-2A — Q92828 (reviewed: Q92828)

Alternative names: IR10, WD repeat-containing protein 2

All UniProt accessions (1): Q92828

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Binds actin. Component of the N-Cor repressor complex, at least composed of NCOR1, NCOR2, HDAC3, TBL1X, TBL1R, CORO2A and GPS2.

Similarity. Belongs to the WD repeat coronin family.

RefSeq proteins (2): NP_003380, NP_438171* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR015048	DUF1899	Domain
IPR015505	Coronin	Family
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR019775	WD40_repeat_CS	Conserved_site
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily

Pfam: PF00400, PF08953, PF16300

UniProt features (15 total): repeat 7, sequence conflict 4, sequence variant 2, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92828-F1	85.12	0.75

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 210 (showing top): TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_DN, YAATNRNNNYNATT_UNKNOWN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, MYOD_01, GOBP_ACTIN_FILAMENT_ORGANIZATION, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, chr9q22, GOMF_ACTIN_BINDING, E12_Q6, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN, RODRIGUES_DCC_TARGETS_DN, GOCC_APICAL_PART_OF_CELL, GOCC_TRANSCRIPTION_REPRESSOR_COMPLEX

GO Biological Process (1): intracellular signal transduction (GO:0035556)

GO Molecular Function (3): actin filament binding (GO:0051015), actin binding (GO:0003779), protein binding (GO:0005515)

GO Cellular Component (2): brush border (GO:0005903), transcription repressor complex (GO:0017053)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular anatomical structure	1
signal transduction	1
actin binding	1
protein-containing complex binding	1
cytoskeletal protein binding	1
binding	1
microvillus	1
apical part of cell	1
cluster of actin-based cell projections	1
transcription regulator complex	1

Protein interactions and networks

STRING

1818 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CORO2A	COP1	Q8NHY2	750
CORO2A	WDR1	O75083	567
CORO2A	SOD2	P04179	500
CORO2A	ACTB	P02570	498
CORO2A	NISCH	Q9Y2I1	480
CORO2A	GPS2	Q13227	479
CORO2A	POTEF	A5A3E0	477
CORO2A	HDAC3	O15379	447
CORO2A	TBL1XR1	Q9BZK7	417
CORO2A	RFLNA	Q6ZTI6	414
CORO2A	ITGB6	P18564	392
CORO2A	NCOR1	O75376	391
CORO2A	DET1	Q7L5Y6	382
CORO2A	CFL2	Q9Y281	379
CORO2A	TAB2	Q9NYJ8	371

IntAct

84 interactions, top by confidence:

A	B	Type	Score
SMARCB1	ARID1A	psi-mi:“MI:0914”(association)	0.860
CORO2A	NR1H2	psi-mi:“MI:0915”(physical association)	0.580
NR1H2	CORO2A	psi-mi:“MI:0915”(physical association)	0.580
FXN	CORO2A	psi-mi:“MI:0915”(physical association)	0.560
CORO2A	LITAF	psi-mi:“MI:0915”(physical association)	0.560
NEURL4	APBB1	psi-mi:“MI:0914”(association)	0.530
CSN2	PPP3CC	psi-mi:“MI:0914”(association)	0.530
CSN2	CRYBB3	psi-mi:“MI:0914”(association)	0.530
DBN1	SVIL	psi-mi:“MI:0914”(association)	0.530
SSH1	GSN	psi-mi:“MI:0914”(association)	0.530
BCLAF1	CORO2A	psi-mi:“MI:0915”(physical association)	0.500
CORO2A	BCLAF1	psi-mi:“MI:0914”(association)	0.500
THRAP3	HNRNPC	psi-mi:“MI:0914”(association)	0.480
CORO2A	BCLAF1	psi-mi:“MI:0915”(physical association)	0.400
THAP4	CORO2A	psi-mi:“MI:0915”(physical association)	0.400
AURKA	CORO2A	psi-mi:“MI:0915”(physical association)	0.370
CORO2A	BUB1	psi-mi:“MI:0915”(physical association)	0.370
CORO2A	DCC	psi-mi:“MI:0915”(physical association)	0.370
DLC1	CORO2A	psi-mi:“MI:0915”(physical association)	0.370
NRAS	CORO2A	psi-mi:“MI:0915”(physical association)	0.370
CORO2A	RB1	psi-mi:“MI:0915”(physical association)	0.370
SMAD2	CORO2A	psi-mi:“MI:0915”(physical association)	0.370
Dctn3		psi-mi:“MI:0914”(association)	0.350
ANLN	PLEKHG3	psi-mi:“MI:0914”(association)	0.350

BioGRID (95): CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS), CORO2A (Affinity Capture-MS)

ESM2 similar proteins: A0A1W2PQ27, A0A1W2PQ64, A0A1W2PQC6, A0A1W2PQD8, A0A1W2PQJ5, A0A1W2PR75, A2AV36, A4QN59, A6QQV6, D4A1F2, F1RA39, G5E8F4, J9SQF3, O00142, O42868, O55239, O95050, O95932, O97972, P0CR76, P0CR77, P10938, P40261, P40936, P53538, Q01841, Q22453, Q32LP9, Q4R7D0, Q566Y1, Q5M9G7, Q5RFR7, Q5U4E8, Q5XG58, Q62160, Q6C195, Q6CQ61, Q6DE00, Q6FMU7, Q6PCI6

Diamond homologs: A1CF18, A6ZPA9, A7RHG8, A8IR43, B0W517, B0XAF3, B3MJV8, B3N534, B3RQN1, B4GT01, B4HWV6, B4JPT9, B4KKN1, B4LS78, B4MU54, B4P116, B4Q9T6, B5DG67, B6K1G6, B6QC06, B7PY76, C4JZS6, C4R6H3, D1ZEM6, D5GBI7, G0SA60, O14021, O35142, O35828, O48847, O54929, O55029, P40066, P41318, P53699, P57737, P61480, Q04305, Q05B17, Q0D0X6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 86 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by ALK fusions and activated point mutants	5	15.3×	6e-03

GO biological processes:

GO term	Partners	Fold	FDR
actin filament organization	6	10.0×	4e-03
actin cytoskeleton organization	8	8.9×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

117 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	93
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1750 predictions. Top by Δscore:

Variant	Effect	Δscore
9:98124903:CAA:C	acceptor_gain	1.0000
9:98124904:AAC:A	acceptor_loss	1.0000
9:98124906:C:CC	acceptor_gain	1.0000
9:98124906:C:CG	acceptor_loss	1.0000
9:98124907:T:C	acceptor_loss	1.0000
9:98128257:CTGA:C	acceptor_gain	1.0000
9:98128261:C:CC	acceptor_gain	1.0000
9:98128601:CCTTA:C	donor_loss	1.0000
9:98128603:TTA:T	donor_loss	1.0000
9:98128604:TA:T	donor_loss	1.0000
9:98128605:A:AC	donor_gain	1.0000
9:98128605:AC:A	donor_gain	1.0000
9:98128606:C:A	donor_loss	1.0000
9:98128606:C:CC	donor_gain	1.0000
9:98128606:CC:C	donor_gain	1.0000
9:98128606:CCCG:C	donor_gain	1.0000
9:98128717:CAC:C	acceptor_gain	1.0000
9:98128718:ACC:A	acceptor_loss	1.0000
9:98128720:C:CC	acceptor_gain	1.0000
9:98128720:CTGA:C	acceptor_loss	1.0000
9:98128721:T:G	acceptor_loss	1.0000
9:98129790:TTACC:T	donor_loss	1.0000
9:98129791:T:TG	donor_loss	1.0000
9:98129792:A:AC	donor_gain	1.0000
9:98129792:ACC:A	donor_loss	1.0000
9:98129793:C:CC	donor_gain	1.0000
9:98129793:C:T	donor_loss	1.0000
9:98129793:CCGAT:C	donor_gain	1.0000
9:98129887:CTCC:C	acceptor_gain	1.0000
9:98129888:TCC:T	acceptor_gain	1.0000

AlphaMissense

3453 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:98128671:C:G	R339P	0.999
9:98134824:A:C	S150R	0.999
9:98134824:A:T	S150R	0.999
9:98134826:T:G	S150R	0.999
9:98134856:A:G	W140R	0.999
9:98134856:A:T	W140R	0.999
9:98137622:A:G	W90R	0.999
9:98137622:A:T	W90R	0.999
9:98133072:C:G	R205P	0.998
9:98137594:G:T	A99D	0.998
9:98157515:G:T	A49E	0.998
9:98157617:A:T	V15D	0.998
9:98128191:A:G	W384R	0.997
9:98128191:A:T	W384R	0.997
9:98128236:A:C	Y369D	0.997
9:98128617:A:T	V357E	0.997
9:98128666:A:C	Y341D	0.997
9:98132207:C:G	R248P	0.997
9:98133208:A:G	W160R	0.997
9:98133208:A:T	W160R	0.997
9:98134946:A:G	W110R	0.997
9:98134946:A:T	W110R	0.997
9:98137636:A:T	V85D	0.997
9:98157476:A:T	V62D	0.997
9:98157516:C:G	A49P	0.997
9:98130969:A:C	Y286D	0.996
9:98137580:C:G	D104H	0.996
9:98137586:A:G	S102P	0.996
9:98137592:A:G	S100P	0.996
9:98157611:C:T	G17D	0.996

dbSNP variants (sampled 300 via entrez): RS1000063583 (9:98134364 C>G,T), RS1000065143 (9:98181579 T>C), RS1000073095 (9:98166250 C>T), RS1000142073 (9:98141132 A>G), RS1000147714 (9:98166626 A>T), RS1000150208 (9:98133895 T>C), RS1000191362 (9:98125288 G>A), RS1000193106 (9:98189950 T>G), RS1000224380 (9:98190194 C>A,T), RS1000302771 (9:98143256 C>T), RS1000346397 (9:98188623 G>A), RS1000351424 (9:98172211 C>G), RS1000355679 (9:98143709 T>C), RS1000366950 (9:98144049 T>C), RS1000457815 (9:98137408 C>A,G,T)

Disease associations

OMIM: gene MIM:602159 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): myoepithelial tumor (MONDO:0002380)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006168_7	Pulse pressure x alcohol consumption interaction (2df test)	1.000000e-09
GCST008514_15	Peginterferon alfa-2a treatment response in chronic hepatitis B infection	5.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004329	alcohol drinking
EFO:0005763	pulse pressure measurement
EFO:0010103	response to peginterferon alfa-2a

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009208	Myoepithelioma	C04.557.435.585

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

59 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, increases methylation, affects cotreatment	9
trichostatin A	increases expression, affects cotreatment	3
sodium arsenite	decreases expression, affects cotreatment, increases abundance	3
Benzo(a)pyrene	decreases expression, increases methylation	3
Tretinoin	increases expression	3
entinostat	increases expression, affects cotreatment	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Air Pollutants	decreases expression, affects expression, increases abundance	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
pirinixic acid	increases activity, affects binding, decreases expression	1
deoxynivalenol	decreases expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	affects expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
benzo(e)pyrene	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
nutlin 3	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	increases expression	1
Arsenic Trioxide	decreases expression	1
Amiodarone	increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1

Clinical trials (associated diseases)

5 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03600649	PHASE1	UNKNOWN	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
NCT05266196	PHASE1/PHASE2	UNKNOWN	A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
NCT06239272	PHASE1/PHASE2	RECRUITING	NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
NCT06625190	PHASE1/PHASE2	RECRUITING	Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT06244420	Not specified	COMPLETED	Malignant Myoepithelioma of Bone and Soft Tissues: Diagnostic Imaging and Histology in Relation to Prognosis